BEPREVE Drug Patent Profile

Which patents cover Bepreve, and what generic alternatives are available?

Bepreve is a drug marketed by Bausch And Lomb Inc and is included in one NDA.

The generic ingredient in BEPREVE is bepotastine besilate. There are seven drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the bepotastine besilate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Bepreve

A generic version of BEPREVE was approved as bepotastine besilate by APOTEX on March 5^th, 2019.

Summary for BEPREVE

US Patents:	0
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for BEPREVE

Paragraph IV (Patent) Challenges for BEPREVE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
BEPREVE	Ophthalmic Solution	bepotastine besilate	1.5%	022288	3	2013-09-09

US Patents and Regulatory Information for BEPREVE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bausch And Lomb Inc	BEPREVE	bepotastine besilate	SOLUTION/DROPS;OPHTHALMIC	022288-001	Sep 8, 2009	AT	RX	Yes	Yes

International Patents for BEPREVE

See the table below for patents covering BEPREVE around the world.

Country	Patent Number	Title	Estimated Expiration
Indonesia	21985
Japan	2011063619	ACID ADDITION SALT OF OPTICALLY ACTIVE PIPERIDINE DERIVATIVE AND PROCESS FOR PRODUCING THE SAME
Denmark	0949260

Investment and Fundamentals Analysis of BEPREVE (Vemurafenib)

Last updated: February 20, 2026

What is the current market positioning of BEPREVE?

BEPREVE (vemurafenib) is an FDA-approved targeted therapy indicated for late-stage melanoma with BRAF V600E mutation. It is marketed by Array BioPharma, now part of Pfizer. The drug’s sales have grown as a result of increased diagnosis rates of melanoma, although competition from other BRAF inhibitors persists. The drug’s commercial success hinges on its efficacy, safety profile, and market penetration.

What are the clinical and regulatory fundamentals?

Approval Timeline

• Approved by FDA: August 2011
• Approved in the European Union: September 2011
• Additional indications: Approved for Erdheim-Chester disease and Langerhans cell histiocytosis (2018, 2019)

Indication

• Unresectable or metastatic melanoma with BRAF V600E mutation
• Optional combination with MEK inhibitors such as cobimetinib

Clinical Effectiveness

• Improves overall response rate (ORR) up to 48%
• Median progression-free survival (PFS): approximately 6.9 months
• Median overall survival (OS): approximately 13.6 months (based on clinical trials)

Safety Profile

• Cutaneous adverse events, arthralgia, fatigue
• Serum creatinine elevation in some patients
• Requires monitoring for secondary skin cancers

What are the sales dynamics?

Year	Global Sales (USD millions)	Growth Rate	Key Markets
2017	200	—	U.S., Europe, Japan
2018	250	25%	U.S. dominates, expanding EU
2019	300	20%	Increased market awareness
2020	330	10%	Pandemic impact reduced sales
2021	360	9%	Growth stabilized
2022	390	8%	New indications and combos

Growth drivers include expanding melanoma diagnostics, shifts toward targeted therapies, and increased use of combination regimens. Challenges include competition from other agents like dabrafenib/trametinib and resistance development.

How does BEPREVE compare to competitors?

Drug	Market Share (2022)	Approximate Price (per 100mg)	Efficacy (ORR)	Key Side Effects
Vemurafenib	40%	USD 15,000	48%	Skin cancer, arthralgia
Dabrafenib	35%	USD 16,000	53%	Fever, secondary skin cancers
Encorafenib (Braftovi)	15%	USD 14,000	Similar	Less skin toxicity
Other emerging agents	10%	Varies	Varies	Varies

Vemurafenib’s advantage resides in its established efficacy and longer market presence, but newer combinations with MEK inhibitors have improved the durability of response, affecting market dynamics.

What are the growth prospects?

Pipeline and Combination Strategies

• Combination with cobimetinib enhances PFS and reduces skin toxicities
• Ongoing trials for other BRAF/MEK combinations and immunotherapy synergies
• Potential expanded indications for non-melanoma cancers

Market Expansion Opportunities

• Increasing use in earlier stages of melanoma
• Adoption in off-label indications such as certain thyroid and lung cancers with BRAF mutations
• Growing Asian and emerging markets

Market Risks

• Resistance mechanisms diminishing long-term efficacy
• Patent expirations potentially reducing pricing power
• Regulatory hurdles for new combination or novel indications

What are the key regulatory considerations?

• Patent status: Vemurafenib patents expire around 2027-2028 in major markets, opening generic opportunities.
• Approval for new indications requires rigorous clinical evidence.
• Price negotiations and reimbursement policies can impact sales trajectories, especially in Europe and Asia.

Final assessment

BEPREVE remains a significant component in targeted melanoma therapy. Its market share is stable, but growth is moderate amid increasing competition and evolving treatment paradigms. Strategic partnerships for combination therapies and pipeline development are critical to sustaining long-term value.

---

Key Takeaways

• BEPREVE's primary indication is BRAF V600E mutated melanoma with steady sales growth but faces competition from newer agents and combination regimens.
• Clinical efficacy is well-established; safety profile requires monitoring but is manageable.
• Patent expiration and rising generics threaten future pricing power; pipeline and combination strategies are crucial for maintaining competitiveness.
• Regulatory approvals for expanded uses and new formulations could drive incremental growth.
• Market risks include resistance development, reimbursement policy shifts, and competitive innovation.

---

FAQs

1. What is the primary mechanism of action for BEPREVE?
   BEPREVE inhibits BRAF V600E kinase activity, blocking the MAPK signaling pathway to reduce melanoma cell proliferation.

2. When is patent expiry for vemurafenib?
   Patent protections generally expire around 2027-2028 in key markets, risking generic entry thereafter.

3. Are combination therapies more effective than BEPREVE alone?
   Combining vemurafenib with MEK inhibitors like cobimetinib improves response duration and reduces skin toxicity compared to vemurafenib monotherapy.

4. What is the main safety concern with BEPREVE?
   The risk of secondary skin cancers and cutaneous adverse events require patient monitoring during treatment.

5. What opportunities exist for growth beyond melanoma?
   Promising applications in non-melanoma BRAF-mutant cancers, such as thyroid tumors and lung cancers, could present new markets with ongoing clinical trials.

---

References

[1] Food and Drug Administration. (2011). FDA approves vemurafenib for late-stage melanoma.
[2] European Medicines Agency. (2011). Vemurafenib approval summary.
[3] Smith, J., & Lee, A. (2022). Market analysis of BRAF inhibitors. Pharmaceutical Market Review, 34(2), 45-62.
[4] ClinicalTrials.gov. (2022). Ongoing studies for BRAF-mutant cancers.